Hercules, CA — December 6, 2012 — Bio-Rad Laboratories, Inc. today announced the launch of the CFX qualification plate, an easy-to-use tool for accurately verifying the performance of any CFX real-time PCR system, providing researchers with confidence in their results.
Preloaded with an optimized master mix containing Bio-Rad’s SsoAdvanced™ SYBR® Green supermix, the CFX qualification plate provides a five-point standard curve, two unknown groups, and no-template controls, allowing for the rapid determination of a pass/fail instrument performance result.
Included in Bio-Rad’s CFX Manager™ software is the new qualification plate check tool for analyzing the CFX qualification plate data. The tool uses an algorithm to determine a pass/fail performance result based on two criteria: twofold discrimination with a 99.7% confidence level and single-product melt peaks for the two unknowns. A passing result indicates good optical performance and uniform thermal block control.
The CFX qualification plate joins Bio-Rad’s new PCR instrument validation tools for verifying Bio-Rad’s real-time PCR detection systems.
For more information about the CFX qualification plate, please visit http://www.bio-rad.com/cfxqualification.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
312-997-2436 x 112